Unique Anti-Glioblastoma Activities of Hypericin Are at the Crossroad of Biochemical and Epigenetic Events and Culminate in Tumor Cell Differentiation

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Dror, Naama ^a   Mandel, Mathilda ^b   Lavie, Gad ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

DNA METHYLTRANSFERASE 1; GLIAL FIBRILLARY ACIDIC PROTEIN; HEAT SHOCK PROTEIN 90; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE H3; HISTONE H4; HYPERICIN; MESSENGER RNA; NEURON SPECIFIC NUCLEAR PROTEIN; POLYCOMB REPRESSIVE COMPLEX 2; TRANSCRIPTION FACTOR EZH2;

ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMATIN STRUCTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOARCHITECTURE; DNA METHYLATION; DNMT1 GENE; EPIGENETICS; EZH2 GENE; GENE; GFAP GENE; GLIOBLASTOMA; HDAC1 GENE; HDAC2 GENE; HDAC3 GENE; HISTONE ACETYLATION; HUMAN; HUMAN CELL; NERVE CELL DIFFERENTIATION; PROGENY; PROTEIN DEGRADATION; TRANSCRIPTION INITIATION; UBIQUITINATION;

CELL CYCLE; CELL DIFFERENTIATION; CELL LINE, TUMOR; DNA METHYLATION; EPIGENESIS, GENETIC; GLIOBLASTOMA; HUMANS; PERYLENE;

EID: 84884180719     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0073625     Document Type: Article

References (40)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987- 996.
2. Cadieux B, Ching TT, VandenBerg SR, Costello JF, (2006) Genome-wide hypomethylation in human glioblastomas associated with specific copy number alteration, methylenetetrahydrofolate reductase allele status, and increased proliferation. Cancer Res 66: 8469-8476.
3. Moss TJ, Wallrath LL, (2007) Connections between epigenetic gene silencing and human disease. Mutat Res 618: 163-174.
4. Sparmann A, van Lohuizen M, (2006) Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer 6: 846-856.
5. Cao R, Zhang Y, (2004) The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3. Curr Opin Genet Dev 14: 155-164.
6. Crea F, Hurt EM, Farrar WL, (2010) Clinical significance of Polycomb gene expression in brain tumors. Mol Cancer 9: 265.
7. Van Der Vlag J, Otte AP, (1999) Transcriptional repression mediated by the human polycomb-group protein EED involves histone deacetylation. Nat Genet 23: 474-478.
8. Vire E, Brenner C, Deplus R, Blanchon L, Fraga M, et al. (2006) The Polycomb group protein EZH2 directly controls DNA methylation. Nature 439: 871-874.
9. Ehrlich M, (2002) DNA methylation in cancer: too much, but also too little. Oncogene 21: 5400-5413.
10. Esteller M, (2007) Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 8: 286-298.
11. Kanai Y, Hirohashi S, (2007) Alterations of DNA methylation associated with abnormalities of DNA methyltransferases in human cancers during transition from a precancerous to a malignant state. Carcinogenesis 28: 2434-2442.
12. Fanelli M, Caprodossi S, Ricci-Vitiani L, Porcellini A, Tomassoni-Ardori F, et al. (2008) Loss of pericentromeric DNA methylation pattern in human glioblastoma is associated with altered DNA methyltransferases expression and involves the stem cell compartment. Oncogene 27: 358-365.
13. Kreth S, Thon N, Eigenbrod S, Lutz J, Ledderose C, et al. (2011) O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation. PLoS One 18 6(2): e17156.
14. Timmermann S, Lehrmann H, Polesskaya A, Harel-Bellan A, (2001) Histone acetylation and disease. Cell Mol Life Sci 58: 728-736.
15. Mack GS, (2006) Epigenetic cancer therapy makes headway. J Natl Cancer Inst 98: 1443-1444.
16. Bernstein BE, Meissner A, Lander ES, (2007) The mammalian epigenome. Cell 128: 669-681.
17. Bolden JE, Peart MJ, Johnstone RW, (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5: 769-784.
18. Blank M, Mandel M, Keisari Y, Meruelo D, Lavie G, (2003) Enhanced ubiquitinylation of heat shock protein 90 as a potential mechanism for mitotic cell death in cancer cells induced with hypericin. Cancer Res 63: 8241-8247.
19. Barliya T, Mandel M, Livnat T, Weinberger D, Lavie G, (2011) Degradation of HIF-1alpha Under Hypoxia Combined with Induction of Hsp90 Polyubiquitination in Cancer Cells by Hypericin: a Unique Cancer Therapy. PLoS One 6(9): e22849.
20. Lavie G, Mandel M, Hazan S, Barliya T, Blank M, et al. (2005) Anti angiogenic activities of hypericin in vivo: potential for ophthalmologic applications. Angiogenesis 8: 35-42.
21. Sollars V, Lu X, Xiao L, Wang X, Garfinkel MD, et al. (2003) Evidence for an epigenetic mechanism by which Hsp90 acts as a capacitor for morphological evolution. Nat Genet 33: 70-74.
22. Zhao R, Davey M, Hsu YC, Kaplanek P, Tong A, et al. (2005) Navigating the chaperone network: an integrative map of physical and genetic interactions mediated by the hsp90 chaperone. Cell 120: 715-727.
23. Esteller M, (2008) Epigenetics in cancer. N Engl J Med 358: 1148-1159.
24. Ballestar E, Paz MF, Valle L, Wei S, Fraga MF, et al. (2003) Methyl-CpG binding proteins identify novel sites of epigenetic inactivation in human cancer. EMBO J 22: 6335-6345.
25. Keisari Y, (1992) A colorimetric microtiter assay for the quantitation of cytokine activity on adherent cells in tissue culture. J Immunol Methods 146: 155-161.
26. Weisz L, Zalcenstein A, Stambolsky P, Cohen Y, Goldfinger N, et al. (2004) Transactivation of the EGR1 gene contributes to mutant p53 gain of function. Cancer Res 64: 8318-8327.
27. Batty N, Malouf GG, Issa JP, (2009) Histone deacetylase inhibitors as anti-neoplastic agents. Cancer Lett. 280: 192-200.
28. Cheng PY, Lin YP, Chen YL, Lee YC, Tai CC, et al. (2011) Interplay between SIN3A and STAT3 Mediates Chromatin Conformational Changes and GFAP Expression during Cellular Differentiation. PLoS ONE 6(7): e22018.
29. Rajan P, McKay RD, (1998) Multiple routes to astrocytic differentiation in the CNS. J Neurosci 18: 3620-3629.
30. Gerson F, Gescheidt G, Haering P, Mazur Y, Freeman D, et al. (1995) Electron acceptor properties of hypericin and its salts: an ESR/ENDOR and electrochemical study. J Am Chem Soc 117: 11861-11866.
31. Redepenning J, Tao N, (1993) Measurement of formal potentials for hypericin in dimethyl sulfoxide. Photochem Photobiol 58: 532-535.
32. Wong KSK, Houry WA, (2006) Hsp90 at the crossroads of genetics and epigenetics. Cell Res 16: 742-749.
33. Zhou Q, Agoston AT, Atadja P, Nelson WG, Davidson NE, (2008) Inhibition of histone deacetylases promotes ubiquitin-dependent proteasomal degradation of DNA methyltransferase 1 in human breast cancer cells. Mol Cancer Res 6: 873-883.
34. Johnstone RW, (2002) Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 1: 287-299.
35. Li W, Zhao L, Zang W, Liu Z, Chen L, et al. (2011) Histone demethylase JMJD2B is required for tumor cell proliferation and survival and is overexpressed in gastric cancer. Biochem. Biophys Res Commun 416: 372-378.
36. Simon JA, Lange CA, (2008) Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutation Res 647: 21-29.
37. Couldwell WT, Surnock AA, Tobia AJ, Cabana BE, Stillerman CB, et al. (2011) Phase 1/2 study of orally administered synthetic hypericin for treatment of recurrent malignant gliomas. Cancer 117: 4905-4915.
38. Lee KT, Kim JI, Rho YS, Chang SG, Jung JC, et al. (1999) Hypericin induces both differentiation and apoptosis in human promyelocytic leukemia HL-60 cells. Biol Pharm Bull 22: 1271-1274.
39. Kim JI, Park JH, Park HJ, Choi SK, Lee KT, (1998) Induction of differentiation of the human histocytic lymphoma cell line U-937 by hypericin. Arch Pharm Res 21: 41-45.
40. Campos B, Bermejo JL, Han L, Felsberg J, Ahmadi R, et al. (2011) Expression of nuclear receptor corepressors and class I histone deacetylases in astrocytic gliomas. Cancer Sci 102: 387-392.